Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia - priME Oncology
Webcast
Webcast

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

View Activity

Activity Overview

Expand your understanding of acute myeloid leukemia (AML) targeted therapy options and how cytogenetics influences treatment decisions with this webcast of our satellite symposium at the 22nd Congress of the European Hematology Association in Madrid, Spain. Initial discussion will focus on AML subgroups classification. From there, options in initial therapy and relapsed or refractory disease will be featured. Finally, new targeted options will be examined in detail.

This engaging activity will provide a foundation for further exploration of new treatment options in newly-diagnosed and relapsed/refractory disease.

Topics

Examining genetics and genomics in AML in 2017
Elli Papaemmauil, PhD 

Personalizing initial therapy in AML
Francesco Lo Coco, MD

What’s on the horizon for relapsed/refractory AML?
Lisa Pleyer, MD

A deeper dive into AML subgroups
Miguel Sanz, MD

prIME Points™
Miguel Sanz, MD

FACULTY

  • Miguel Sanz, MDValencia University Medical School
    University Hospital La Fe
    Valencia, Spain
  • Francesco Lo Coco, MDUniversity Tor Vergata
    Rome, Italy
  • Lisa Pleyer, MDSalzburg Cancer Research Institute
    Salzburg, Austria
  • Elli Papaemmanuil, PhDMemorial Sloan Kettering Cancer Center
    New York, New York, United States

Target Audience

The proposed educational activity is specifically designed to meet the needs of hematologists, oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with AML.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Compare current AML classification systems and the role that cytogenetics plays in them
  • Describe molecularly-defined subtypes of AML
  • Evaluate current initial therapeutic strategies in newly-diagnosed AML based on patient and disease characteristics
  • Identify novel agents being investigated in relapsed/refractory AML
View Activity

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by grants from Celgene, Helsinn Healthcare SA, and Novartis Oncology.

Activity Date

RELEASE DATE
July 21, 2017

EXPIRATION DATE
July 21, 2018